

ONE HUNDRED EIGHTEENTH CONGRESS

**Congress of the United States**  
**House of Representatives**

COMMITTEE ON ENERGY AND COMMERCE

2125 RAYBURN HOUSE OFFICE BUILDING  
WASHINGTON, DC 20515-6115

Majority (202) 225-3641  
Minority (202) 225-2927

July 7, 2023

Dr. Alexis A. Thompson, MD, MPH  
Chief of Division of Hematology, Children's Hospital of Philadelphia  
Professor of Pediatrics, University of Pennsylvania Perelman School of Medicine  
3401 Civic Center Boulevard  
Philadelphia, PA 19104

Dear Dr. Thompson:

Thank you for appearing before the Subcommittee on Health on Wednesday, June 14, 2023, to testify at the hearing entitled "Examining Proposals that Provide Access to Care for Patients and Support Research for Rare Diseases."

Pursuant to the Rules of the Committee on Energy and Commerce, the hearing record remains open for ten business days to permit Members to submit additional questions for the record, which are attached. The format of your responses to these questions should be as follows: (1) the name of the Member whose question you are addressing, (2) the complete text of the question you are addressing in bold, and (3) your answer to that question in plain text.

To facilitate the printing of the hearing record, please respond to these questions and requests with a transmittal letter by the close of business on Friday, July 21, 2023. Your responses should be mailed to Jolie Brochin, Legislative Clerk, Committee on Energy and Commerce, 2125 Rayburn House Office Building, Washington, D.C. 20515 and e-mailed in Word format to [Jolie.Brochin@mail.house.gov](mailto:Jolie.Brochin@mail.house.gov).

Thank you again for your time and effort preparing and delivering testimony before the Subcommittee.

Sincerely,



Brett Guthrie  
Chair  
Subcommittee on Health

cc: Anna Eshoo, Ranking Member, Subcommittee on Health

[Dr. Thompson did not answer submitted questions for the record by the time of publication. Replies received after publication will be retained in committee files and made available at <https://docs.house.gov/Committee/Calendar/ByEvent.aspx?EventID=116121>.]

**The Honorable Earl L. “Buddy” Carter**

- 1) I have a question about H.R. 1672, the Sickle Cell Disease Comprehensive Care Act, which you mention in your testimony. That legislation would direct CMS to create a Medicaid demonstration program in up to 10 states to improve access to comprehensive, high-quality outpatient care for individuals with sickle cell disease. I do not think that all services need to be matched by the federal government at 100 percent as that bill specifies. But the idea of providing comprehensive and coordinated care is a good idea. This Committee has previously supported a Medicaid Health Home model, which is a state option to receive enhanced funding [90 percent match] for a time-limited basis to help fund care coordination. As I understand it, nearly half the states have implemented more than 30 Health Home programs and have seen really positive results – including lower costs and better outcomes. Many have continued the Health Home even after enhanced funding expired. Would you be willing to explore whether the goals of The Comprehensive Care Act could be achieved through a modification to this Health Home model? There are thousands of individuals in Georgia in Medicaid with sickle cell disease that this idea might help.
  
- 2) How does information collected through the CDC Sickle Cell Data Collection program help strengthen other federal programs such as the HRSA Treatment Demonstration Program to improve and extend the lives of people with SCD?